Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trialLancet Neurol 2022 Aug 01;21(8)693-703, A Svenningsson, T Frisell, J Burman, J Salzer, K Fink, S Hallberg, J Hambraeus, M Axelsson, FA Nimer, P Sundström, M Gunnarsson, R Johansson, J Mellergård, I Rosenstein, A Ayad, I Sjöblom, A Risedal, P de Flon, E Gilland, J Lindeberg, F Shawket, F Piehl, J Lycke
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.